Stay updated on Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial
Sign up to get notified when there's something new on the Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial page.

Latest updates to the Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe study protocol document version on the page was updated from v3.6.5 to v3.6.6, indicating a newer protocol release. This reflects an administrative update to the Study Protocol and Statistical Analysis Plan documentation on the page.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe study’s locations were updated with many new enrollment sites across China (e.g., Hangzhou, Shanghai, Chengdu, Jinan, Nanjing, Shenyang, Qingdao, Hangzhou again) and other regions, while a large number of previously listed sites were removed, resulting in a larger overall footprint (up to 380 locations) compared to before.SummaryDifference4%

- Check30 days agoChange DetectedThe page's revision label was updated from v3.6.4 to v3.6.5, indicating a newer release. There is no indication of user-facing content changes to study details or page layout.SummaryDifference0.0%

- Check44 days agoChange DetectedThe page now shows Revision: v3.6.4, replacing Revision: v3.6.3, signaling a minor page-version update rather than a change to the study details.SummaryDifference0.0%

- Check66 days agoChange DetectedA new platform revision tag v3.6.3 was added, replacing v3.6.2, indicating a software update rather than changes to study content.SummaryDifference0.0%

- Check73 days agoChange DetectedNew recruitment, sponsor, and study-document links were added to the Study Details page. Items include BMS Clinical Trial Patient Recruiting, BMS Clinical Trial Information, Mirati Therapeutics Inc., and a PDF of the Study Protocol and Statistical Analysis Plan, along with IPD data-sharing notes.SummaryDifference100%

Stay in the know with updates to Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial page.